Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer

24 Oct 2016

Abstract excerpt

Significance Aggressive variant prostate cancer (AVPC) is a clinically defined tumor with neuroendocrine or small-cell differentiation, visceral metastases, low prostate-specific antigen, androgen receptor insensitivity, and poor/brief responses to androgen-deprivation or platinum-based chemotherapy. AVPC incidence has markedly increased, yielding an unmet diagnostic/therapeutic need. Here we adapted a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Prostate Cancer Treatment and Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27791181
DOI: 10.1073/pnas.1615400113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancerPMID 27791181Read ↗

A survivin-driven tumour-activatable minicircle system for prostate cancer theranosticsSemantic proximity Read ↗

Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for <sup>18</sup>F-FDG Imaging of PSMA-Suppressed TumorsSemantic proximity Read ↗

MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancerSemantic proximity Read ↗

Circulating tumor cell characterization and classification by novel combinatorial dual-color (CoDuCo) in situ hybridization and supervised machine learningSemantic proximity Read ↗

<p class="MsoNormal" style="margin-bottom: 12.0pt; text-align: left; mso-line-height-alt: 14.0pt; layout-grid-mode: char; mso-layout-grid-align: none;" align="left">Evaluation of <sup>177</sup>Lu-PSMA-617 Based Targeted Radioligand Therapy with X-Ray Stimulated PSMA Relocation in the <em>PiggyBac</em> Reporter Gene Engineered Orthotopic Prostate Tumor ModelSemantic proximity Read ↗

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived XenograftsSemantic proximity Read ↗

Dual-Tracer 18 F-FDG and 68 Ga-PSMA PET/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy.Semantic proximity Read ↗

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer.Semantic proximity Read ↗

PSMA-CAR-T Cells for Metastatic Castration-Resistant Prostate Cancer: An Integrated Framework for Translational OptimizationSemantic proximity Read ↗

Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapySemantic proximity Read ↗

Microenvironment-Guided Evolution of ssDNA-SWCNT Probes for Selective Recognition of Aggressive Prostate Cancer Phenotypes.Semantic proximity Read ↗

Targeting RET Kinase in Neuroendocrine Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.